Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Metastatic Pancreatic Cancer
NCT00474812Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2007
- Primary completion
- Jan 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in pancreatic adenocarcinoma (PDAC), sponsored by National Cancer Institute. Started May 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00474812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00474812.